Below are the most recent publications written about "Biomarkers, Tumor" by people in Profiles.
-
Roy R, Schunkert EM, Olivova P, Gilar M, Geromanos S, Li GZ, Gebler J, Dagher A, El-Hayek A, Aldakhlallah R, Staffa SJ, Zurakowski D, Lotz M, Pories S, Moses MA. Identification of vitronectin as a potential non-invasive biomarker of metastatic breast cancer using a label-free LC-MS/MS approach. Breast Cancer Res. 2025 May 29; 27(1):94.
-
Freitas AJA, Causin RL, Calfa S, Santana IVV, Balie M, Hirai W, Laus AC, Araujo HS, Hidalgo Filho CM, de Oliveira Bombarda F, da Silva VD, Evangelista AF, de P?dua Souza C, Reis RM, Marques MMC. Exploring the Nottingham classification: assessing gene expression profiles in breast cancer patients and their association with outcomes. Breast Cancer Res Treat. 2025 Jul; 212(2):237-250.
-
Sorroche BP, de Jesus Teixeira R, de Souza VG, Tosi IC, Tostes K, Laus AC, Santana IVV, de Lima Vazquez V, Arantes LMRB. CD24, NFIL3, FN1, and KLRK1 signature predicts melanoma immunotherapy response and survival. J Mol Med (Berl). 2025 Jun; 103(6):725-737.
-
Biran N, Dhakal B, Niesvizky R, Lentzsch S, Bhutani D, McKay JT, Vesole DH, Nooka A, Paul B, Hari PN, D'Ambrosi S, Kuiper R, van Vliet M, Siegel D, Usmani SZ, van Rhee F. Enhancing risk stratification and treatment decision in multiple myeloma with SKY92 gene expression profiling in real-world data. Br J Haematol. 2025 Jun; 206(6):1642-1653.
-
Dora D, Revisnyei P, Pasic A, Galffy G, Dulka E, Mihucz A, Rosk? B, Szincsak S, Iliuk A, Weiss GJ, Lohinai Z. Host and bacterial urine proteomics might predict treatment outcomes for immunotherapy in advanced non-small cell lung cancer patients. Front Immunol. 2025; 16:1543817.
-
Zhu X, Meng X, Mochel MC, Wiliams EA, Dresser K, Tomaszewicz K, Hutchinson L, Bledsoe JR. CYLD-mutated anal squamous cell carcinoma: An uncommon entity associated with cylindroma-like morphology and adverse clinical features. Hum Pathol. 2025 Mar; 157:105765.
-
Kim IE, Oduor C, Stamp J, Luftig MA, Moormann AM, Crawford L, Bailey JA. Incorporation of Epstein-Barr viral variation implicates significance of Latent Membrane Protein 1 in survival prediction and prognostic subgrouping in Burkitt lymphoma. Int J Cancer. 2025 Jun 01; 156(11):2188-2199.
-
Zhou P, Li Z, Liu F, Kwon E, Hsieh TC, Ye S, Vasudevan S, Lee JA, Tran KV, Zhou C. BAMBI integrates biostatistical and artificial intelligence methods to improve RNA biomarker discovery. Brief Bioinform. 2025 Mar 04; 26(2).
-
Simhal AK, Firestone RS, Oh JH, Avutu V, Norton L, Hultcrantz M, Usmani SZ, Maclachlan KH, Deasy JO. High WEE1 expression is independently linked to poor survival in multiple myeloma. Blood Cancer J. 2025 Feb 20; 15(1):22.
-
Nguyen LHD, Nguyen THH, Le VH, Bui VQ, Nguyen LH, Pham NH, Phan TH, Nguyen HT, Tran VS, Bui CV, Vo VK, Nguyen PTN, Dang HHP, Pham VD, Cao VT, Phan NM, Tieu BL, Nguyen GTH, Vo DH, Tran TH, Nguyen TD, Nguyen VTC, Nguyen TH, Tran VU, Le MP, Tran TMT, Nguyen Nguyen M, Van TTV, Nguyen AN, Nguyen TT, Doan NNT, Nguyen HT, Doan PL, Huynh LAK, Nguyen TA, Nguyen HTP, Lu YT, Cao CTT, Nguyen VT, Le Quyen Le T, Luong TL, Doan TKP, Dao TT, Phan CD, Nguyen TX, Pham NT, Nguyen BT, Pham TTT, Le HL, Truong CT, Jasmine TX, Le MC, Phan VB, Truong QB, Tran THL, Huynh MT, Tran TQ, Nguyen ST, Tran V, Tran VK, Nguyen Nguyen H, Nguyen DS, Van Phan T, Do TT, Truong DK, Tang HS, Giang H, Nguyen HN, Phan MD, Tran LS. Prospective validation study: a non-invasive circulating tumor DNA-based assay for simultaneous early detection of multiple cancers in asymptomatic adults. BMC Med. 2025 Feb 14; 23(1):90.